

**EUROMEDLAB Amsterdam 2007****17th IFCC - FESCC European Congress of Clinical Chemistry and Laboratory Medicine****60th National Congress of the Netherlands Society for Clinical Chemistry and Laboratory Medicine****Amsterdam RAI convention centre The Netherlands****3 - 7 June 2007****OPENING CEREMONY**

Sunday 3 June 2007

17.00 - 19.00

Amsterdam RAI convention centre

Welcome addresses

Opening Lectures exploring the central theme of "Water"

J.H. Ravesloot - Lecture on Physiology

G. Schwartz - Lecture on Art

Performances in cooperation with

"The International Dance Theatre"

19.00 - 20.30

INFORMAL GET-TOGETHER PARTY

Amsterdam RAI convention centre

**SCIENTIFIC PROGRAMME**

Lectures and Symposia

**MONDAY 4 JUNE 2007****MORNING SYMPOSIA****Recent developments in parathyroid hormone**

Update on structure-function relationships.

J.Potts, Boston, MA, USA

Which forms of PTH to be measured and why?

J.C. Souberbielle, Paris, France

Intraoperative PTH measurement; cost-effective POCT.

To be announced

Efficacy of PTH treatment.

J. Reeve, Cambridge, UK

**Epigenetics in complex disease**

Adaptation to the conditions of existence.

F.A.J. Muskiet, Groningen, The Netherlands,

Fundamentals of epigenetics and its relevance to human disease.

R. Feil, Montpellier, France

The epigenetic basis of the "fetal origins of disease".

M.A. Hanson, Southampton, UK

The role of epigenetic modification in the development of cancer.

E. Ballestar, Madrid, Spain

**Evidence in action (Joint session of IFCC Committee on evidence-based laboratory medicine and IFCC global campaign on diabetes mellitus task force)**

Standardization of microalbumine.

M.J. McQueen, Hamilton, Canada

Clinical use of microalbumine - results from an international survey.

S. Sandberg, Bergen, Norway

Quality of guidelines for diabetes mellitus: can we do better?

A.R Horvath, Szeged, Hungary

Natriuretic Peptides: what's the evidence in support of their clinical utilization?

R.H. Christenson, Baltimore, U.S.A.

Laboratory related recommendations for screening colorectal cancer: can we trust current guidelines?

J. Watine, Rodez, France

**Standardization in laboratory medicine: the way forward (IFCC Scientific Division)**

Traceability, reference systems and result comparability.

J.C. Forest, Québec, Canada

The JCTLM: goals and ongoing activities.

M.M. Müller, Vienna, Austria

The contribution of the IFCC Scientific Division activities to standardisation.

M. Panteghini, Milano, Italy

Common reference limits as fourth pillar of the reference system theory.

F. Ceriotti, Milano, Italy

**Lunch time:**

POSTER SESSIONS, Lunch Round Tables and Industry Sponsored Workshops

**AFTERNOON SYMPOSIA****Pharmacogenomics and pharmacogenetics**

Pharmacogenomics and cardiovascular drugs.

G. Siest, Nancy, France

Cytochrome P450 enzymes in cancer treatment.

R.H. van Schaik, Rotterdam, The Netherlands

Pharmacogenetics and transplantation.

P. Marquet, Limoges, France

Dose adjustments based on genotype in psychiatry and diabetes.

J. Kirchheiner, Ulm, Germany

#### **Haemoglobinopathies: identification of carriers**

Screening for what?

J. Traeger-Synodinos, Athens, Greece

Screening, why?

R. Galanello, Cagliari, Italy

Screening, who?

B. Gulbis, Brussels, Belgium

Identification of carriers, How?

C. Harteveld, Leiden, The Netherlands

#### **Frontiers in technology and methods - I**

Protein array chips.

P. Bertone, Combridge, UK.

Advances in allergy testing.

To be confirmed

Measuring nucleic acids in plasma.

R.W. Chiu, Hong Kong

Plasmonic technology: a novel approach to ultrasensitive immunoassays.

H. Szmecinski, Baltimore, U.S.A.

#### **INTERACTIVE SESSION**

Clinical cases in metabolic disease

Conductors: M. Duran, F.A. Wijburg, Amsterdam, The Netherlands

#### **TUESDAY 5 JUNE 2007**

##### MORNING SYMPOSIA

#### **Obesity**

Foetal basis of adult disease.

S. Ozanne, Cambridge, UK

Endocrine control of body composition from infancy to puberty.

J.D. Veldhuis, U.S.A., E. Richmond, San Jose, Costa Rica

Is insulin resistance the cause of the metabolic syndrome? To be announced

The rich life of adipocytes.

To be confirmed

**Disease of ageing / biomarkers in neurodegenerative disease**

Assay and significance of biomarkers for Alzheimer disease.

K. Blennow, Gothenburg, Sweden

Mitochondrial dysfunction in Parkinson's disease.

N.W. Wood, London, UK

Candidate genes in the development of cerebrovascular disease.

E. Topic, Zagreb, Croatia

Prion disease.

To be announced

**Advances in laboratory automation and information technology**

Recent topics in laboratory automation and information technology.

J. Dols, Amsterdam, The Netherlands

The European lab tests online network.

M. Klouche, Bremen, Germany

To be announced

To be announced

**Frontiers in technology and methods - II**

Bone-marrow haematopoietic-stem-cell niches.

To be confirmed

Mass spectrometric analysis of protein interactions.

To be confirmed

Metabolomics in the context of systems biology.

J. Van Der Greef, Zeist, The Netherlands

The European EQUALSEC DNA-sequencing program: improving analytical performance and proficiency.

M. Neumaier, Mannheim, Germany

**Lunch time:**

POSTER SESSIONS, Lunch Round Tables and Industry Sponsored Workshops

**AFTERNOON SYMPOSIA****Mass spectrometry in the clinical laboratory**

Recent developments and new applications of tandem mass spectrometry in newborn screening.

D. Matern, Rochester, U.S.A.

Thyroid and steroid hormone measurement by mass spectrometry. L.M. Thienpont, Ghent, Belgium

Analysis of the metabolome related to one carbon metabolism and folate status using a strategy of complementary platforms based on LC-MS/MS and GC-MS/MS.

P.M. Ueland, Bergen, Norway

The value of MS in the unraveling of neurometabolic disorders.

E.A. Struijs, Amsterdam, The Netherlands

#### **Iron metabolism: new insights and consequences for diagnostic medicine**

Overview: new insights in iron metabolism.

R.E. Fleming, St. Louis, U.S.A.

Anemia of chronic disease.

G. Weiss, Innsbruck, Austria

Hereditary hemochromatosis: the hepcidin model as the unifying pathogenetic hypothesis.

D. Swinkels, Nijmegen, The Netherlands

Laboratory management of r-HuEPO therapy.

L. Thomas, Frankfurt, Germany

#### **Late breaking news**

No topics have been selected for this symposium yet to allow inclusion of presentations on the most recent developments in Laboratory Medicine.

#### **INTERACTIVE SESSION: Clinical cases in emergency medicine**

Conductor: P. Gosling, Birmingham, UK

#### **WEDNESDAY 6 JUNE 2007**

##### MORNING SYMPOSIA

#### **Metabolic disease**

The pathology of oxidative phosphorylation disorders.

J.L.G. Nijtmans, Nijmegen, The Netherlands

Laboratory aspects of lysosomal disease.

I. Maire, Lyon, France

Measurement and reference values of holo-transcobalamin and related markers.

E. Nexö, Aarhus, Denmark

Hereditary fructose intolerance: from clinic to protein.

F. Salvatore, Naples, Italy

#### **Bleeding disorders**

Diagnosis and treatment of thromboembolism.

S. Middeldorp, Amsterdam, The Netherlands

Qualitative platelet disorders.

A.T. Nurden, Pessac, France

Pathophysiology of the antiphospholipid syndrome.

Ph. G. de Groot, Utrecht, The Netherlands

Structure and function of blood coagulation factor XIII.

L. Muszbek, Debrecen, Hungary

**Scientific communications (IFCC Communications and Publications Division)**

Recording and distributing digital audio lectures.

C. Webster, Nottingham, UK

Creating interactive educational material.

A. Wootton, Melbourne, Australia

Website conception and information design.

G. Sypniewska, Bydgoszcz, Poland

Improving your presentations and posters.

J.B.H. Lopez, Kuala Lumpur, Malaysia

**Drugs of abuse / therapeutic drug monitoring**

Detection of drugs of abuse in athletes.

D. de Boer, Maastricht, The Netherlands

Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics.

M. Oellerich, Goettingen, Germany

The use of metabolic ratios of psychotropics as indication of genotype: clinical applications.

J. van der Weide, Harderwijk, The Netherlands.

Pathophysiologic effects of selected drugs.

**Lunch time**

POSTER SESSIONS, Lunch Round Tables and Industry Sponsored Workshops

AFTERNOON SYMPOSIA**Osteoporosis and calcium homeostasis**

Review of Vitamin D.

W.D. Fraser, Liverpool, UK

Vitamin D signalling in health and disease.

F. Jakob, Würzburg Germany

Vitamin D in the elderly.

G. Duque, Montreal, Canada

FGF23 a newly recognized regulator of phosphate and vitamin D metabolism.

To be confirmed

**Your future in patient care - II: laboratory responses to a changing regulatory environment**

Serum and tissue banking in relation to clinical information.

J.-E. Litton, Stockholm, Sweden

Contribution of the laboratory to patient safety.

J.D. Kay, Oxford, UK

EC4: Clinical laboratory globalisation: The EU directives

R.T.P. Jansen, Geldrop, The Netherlands

EC4: Recent developments on accreditation and validation.

W. Huisman, The Hague, The Netherlands

**The contribution of laboratory medicine in Kidney disease (IFCC Scientific Division)**

Estimating kidney function using creatinine based equations.

N. Greenberg Rochester, U.S.A.

Cystatin C as estimator of glomerular filtration rate: needs for its definitive implementation.

A. Grubb, Lund, Sweden

Measurement of urinary albumin: analytical aspects influencing its clinical use.

H.A. Morris, Adelaide, Australia

The importance of cardiac biomarkers in end-stage renal disease.

F.S. Apple, Minneapolis, U.S.A.

**INTERACTIVE SESSION: Clinical cases in haematology and immunology**

Conductors:

Immunology

H.H. Hooijkaas, Rotterdam, The Netherlands

Haematology

M.H. van Oers, Amsterdam, The Netherlands

**THURSDAY 7 JUNE 2007**

MORNING SYMPOSIA

**Your future in patient care - I: laboratory responses to changing clinical practice**

Laboratory medicine responses to the "electronic patient".

To be announced

The impact of evidence based guidelines.

To be announced

Outcome measures of point-of-care testing.

To be announced

Personal digital assistants: opportunities for laboratory medicine.

G.H. White, Bedford Park, Australia

**Oncology / tumour markers**

The EU P-Mark project: a quest for new diagnostic and prognostic markers for prostate cancer.

J.A. Schalken, Nijmegen, The Netherlands

The Fecal Occult Blood Test (FOBT) revisited.

C.G. Fraser, Dundee, UK

Tissue inhibitor of metalloproteinases-1 in breast and colon cancer.

N. Brunner, Frederiksburg, Denmark

Ovarian cancer markers: CA 125 and beyond.

R.C. Bast, Houston, U.S.A.

**Clinical and diagnostic immunology**

Diabetes Mellitus type 1

To be announced

Autoimmune Liver Disease

To be announced

Apoptosis and human disease, with specific reference to autoimmune disorders

To be announced

Guillain-Barre Syndrome

To be announced

**Cardiac markers and vascular disease**

Regulation and involvement of heparanase in cancer metastasis and angiogenesis.

I. Vlodavsky, Haifa, Israel

Update on cardiac markers.

P. Venge, Uppsala, Sweden

Strategy for prevention of cardiovascular disease.

To be confirmed

Implementation of cardiac marker measurement according to EC4 guidelines.

The symposium programme of EUROMEDLAB Amsterdam 2007 is still under construction and is subject to modification. This brochure presents the programme up to December 18, 2006. Revisions of the Scientific Programme are available on the congress web site [www.ams2007.org](http://www.ams2007.org) and will be announced in the electronic newsletters.

**CLOSING CEREMONY****THURSDAY 7 JUNE 2007**

13.00 - 13.30

Amsterdam RAI convention centre

Closing Cocktail "See you in Innsbruck 2009"

**ORGANISING SECRETARIAT**

MZ Congressi s.r.l.

Member of the MZ International Group

(Milano, Barcelona, London)

Via Carlo Farini 81 - 20159 Milan (Italy)

Phone: +39 02 66802323 - Fax: +39 02 6686699

E-mail: [euromedlab2007@mzcongressi.com](mailto:euromedlab2007@mzcongressi.com)

**SCIENTIFIC SECRETARIAT**

NVKC

Nederlandse Vereniging voor Klinische Chemie en Laboratoriumgeneeskunde

Catharijnesingel 49A - 3511 GC Utrecht (The Netherlands)

Phone: +31 30 2328623 - Fax: +31 30 2311178

E-mail: [euromedlab@nvkc.nl](mailto:euromedlab@nvkc.nl)